Treatment of neurolept-induced tardive dyskinesia

被引:39
作者
Jankelowitz, Stacey K. [1 ]
机构
[1] Univ Sydney, Cent Clin Sch, Sydney, NSW 2006, Australia
关键词
tardive dyskinesia; treatment; neuroleptic agents; PLACEBO-CONTROLLED TRIAL; DEEP BRAIN-STIMULATION; SCHIZOPHRENIA SPECTRUM DISORDERS; HYPERKINETIC MOVEMENT-DISORDERS; GENETIC ASSOCIATION ANALYSIS; VITAMIN-E TREATMENT; OPEN-LABEL TRIAL; 1A2; CYP1A2; GENE; DOUBLE-BLIND; RECEPTOR GENE;
D O I
10.2147/NDT.S30767
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Tardive dyskinesia (TDK) includes orobuccolingual movements and "piano-playing" movements of the limbs. It is a movement disorder of delayed onset that can occur in the setting of neuroleptic treatment as well as in other diseases and following treatment with other drugs. The specific pathophysiology resulting in TDK is still not completely understood but possible mechanisms include postsynaptic dopamine receptor hypersensitivity, abnormalities of striatal gamma-aminobutyric acid (GABA) neurons, and degeneration of striatal cholinergic interneurons. More recently, the theory of synaptic plasticity has been proposed. Considering these proposed mechanisms of disease, therapeutic interventions have attempted to manipulate dopamine, GABA, acetylcholine, norepinephrine and serotonin pathways and receptors. The data for the effectiveness of each class of drugs and the side effects were considered in turn.
引用
收藏
页码:1371 / 1380
页数:10
相关论文
共 50 条
[31]   Valbenazine for the treatment of tardive dyskinesia [J].
Seeberger, Lauren C. ;
Hauser, Robert A. .
EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) :1279-1287
[32]   VALBENAZINE FOR THE TREATMENT OF TARDIVE DYSKINESIA [J].
Barquero, N. .
DRUGS OF TODAY, 2016, 52 (12) :665-672
[33]   Tardive Dyskinesia [J].
Pratibha G. Aia ;
Gonzalo J. Revuelta ;
Leslie J. Cloud ;
Stewart A. Factor .
Current Treatment Options in Neurology, 2011, 13 :231-241
[34]   Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients [J].
Witter, Daniel P. ;
Holbert, Richard C. ;
Suryadevara, Uma .
EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (10) :965-972
[35]   Dyskinesia: L-dopa-induced and tardive dyskinesia [J].
Rascol, O ;
Fabre, N .
CLINICAL NEUROPHARMACOLOGY, 2001, 24 (06) :313-323
[36]   Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder [J].
Cloud, Leslie J. ;
Zutshi, Deepti ;
Factor, Stewart A. .
NEUROTHERAPEUTICS, 2014, 11 (01) :166-176
[37]   Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia [J].
Lin, Chih-Chun ;
Ondo, William G. .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 389 :48-54
[38]   A case of paliperidone-palmitate-induced tardive dyskinesia [J].
Lally, John ;
Byrne, Fintan ;
Walsh, Elizabeth .
GENERAL HOSPITAL PSYCHIATRY, 2013, 35 (02) :213.e5-213.e7
[39]   Lurasidone-induced tardive dyskinesia [J].
Pendharkar, Shreyas Shrikant ;
Telgote, Shilpa Avinash .
ANNALS OF INDIAN PSYCHIATRY, 2022, 6 (02) :184-185
[40]   TARDIVE-DYSKINESIA INDUCED BY SULPIRIDE [J].
ACHIRON, A ;
ZOLDAN, Y ;
MELAMED, E .
CLINICAL NEUROPHARMACOLOGY, 1990, 13 (03) :248-252